Stembiosys, Inc

StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. We are currently focused on scale-up activities for our patented core technology, CELLvo™ Matrix and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. Our core novel technology platform is an advanced stem cell culture system – CELLvo™ Matrix. CELLvo Matrix™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality.